SCHEMBL3565063

SCHEMBL3565063

Nc1ccc(OCCOc2ccccc2CC(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
CXCL8 P10145 2/20 0.47
PARP10 Q53GL7 1/20 0.46
CFD P00746 1/20 0.46
PLG P00747 1/20 0.46
PLAU P00749 1/20 0.46
F11 P03951 1/20 0.46
KLKB1 P03952 1/20 0.46
F7 P08709 1/20 0.46
TPSB2 P20231 1/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3550795 0.86 FFAR1 (0.51) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL3554563 0.81 MAPT (0.60) ALDH1A1MEN1KMT2ACYP2C9CYP2C19
SCHEMBL11533135 0.80 HPGD (0.58) HPGDRAB9AL3MBTL1CXCL8CFD
SCHEMBL3485836 0.78 L3MBTL1 (0.55) HPGDCYP2C9CYP2C19L3MBTL1CXCL8
SCHEMBL18301818 0.78 L3MBTL1 (0.55) L3MBTL1CXCL8CFDPLGPLAU
SCHEMBL3563411 0.77 AR (0.54) MEN1KMT2AMAPTLMNAPKM
SCHEMBL3560208 0.77 AR (0.54) HPGDMEN1KMT2AL3MBTL1MAPT
SCHEMBL8084869 0.76 L3MBTL1 (0.57) MEN1KMT2AL3MBTL1CXCL8CFD
SCHEMBL8653051 0.76 PPARD (0.58) HPGDCYP2C9CYP2C19RAB9ANPC1
SCHEMBL1151463 0.76 ALDH1A1 (0.53) ALDH1A1KMT2ARAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1761486-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2007-03-14 EP disclosed
WO-2006000288-A1 PHENYLCARBOXYLIC ACID DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 ALDH1A1 61/4885HPGD 389/4885MEN1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.